Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
immunotherapy
Biotech
Immutep's ph. 3 failure surprises analysts, sinks stock
Immutep and the Australian biotech’s investors have been caught off guard by the unexpected failure of its LAG-3 candidate in a phase 3 study.
James Waldron
Mar 13, 2026 9:53am
Dr. Reddy's pens $370M pact for rights to Immutep's LAG-3 agent
Dec 8, 2025 10:55am
BMS-backed Dispatch unveils with $216M, Carl June as cofounder
Jul 23, 2025 6:30am
Hookipa, having sold off vaccines to Gilead, opts to wind down
Jul 21, 2025 3:15am
BioNTech's chief strategy officer heads for the exit
Jul 17, 2025 10:55am
Biopsies illuminate potential of Candel's prostate cancer drug
May 22, 2025 6:57pm
